Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
- PMID: 9537338
- DOI: 10.1161/01.cir.97.12.1129
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
Abstract
Background: Oxidized low-density lipoprotein (ox-LDL) causes endothelial dysfunction in part by decreasing the availability of endothelial nitric oxide (NO). Although HMG CoA reductase inhibitors restore endothelial function by reducing serum cholesterol levels, it is not known whether they can also directly upregulate endothelial NO synthase (ecNOS) activity.
Methods and results: Human saphenous vein endothelial cells were treated with ox-LDL (50 microg/mL thiobarbituric acid reactive substances 12 to 16 nmol/mg) in the presence of HMG CoA reductase inhibitors simvastatin and lovastatin. In a time-dependent manner, ox-LDL decreased ecNOS mRNA and protein levels (91+/-4% and 67+/-8% reduction after 72 hours, respectively). Both simvastatin (1 micromol/L) and lovastatin (10 micromol/L) upregulated ecNOS expression by 3.8-fold and 3.6-fold, respectively, and completely prevented its downregulation by ox-LDL. These effects of simvastatin on ecNOS expression correlated with changes in ecNOS activity. Although L-mevalonate alone did not affect ecNOS expression, cotreatment with L-mevalonate completely reversed ecNOS upregulation by simvastatin. Actinomycin D studies revealed that simvastatin stabilized ecNOS mRNA (tau1/2, 43 versus 35 hours). Nuclear run-on assays and transient transfection studies with a -1.6 kb ecNOS promoter construct showed that simvastatin did not affect ecNOS gene transcription.
Conclusions: Inhibition of endothelial HMG CoA reductase upregulates ecNOS expression predominantly by posttranscriptional mechanisms. These findings suggest that HMG CoA reductase inhibitors may have beneficial effects in atherosclerosis beyond that attributed to the lowering of serum cholesterol by increasing ecNOS activity.
Similar articles
-
Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase.J Biol Chem. 1997 Dec 12;272(50):31725-9. doi: 10.1074/jbc.272.50.31725. J Biol Chem. 1997. PMID: 9395516
-
3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation.Arterioscler Thromb Vasc Biol. 2001 May;21(5):804-9. doi: 10.1161/01.atv.21.5.804. Arterioscler Thromb Vasc Biol. 2001. PMID: 11348878
-
HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.Atherosclerosis. 1997 Aug;133(1):51-9. doi: 10.1016/s0021-9150(97)00118-4. Atherosclerosis. 1997. PMID: 9258407
-
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.Clin Pharmacokinet. 1997 May;32(5):403-25. doi: 10.2165/00003088-199732050-00005. Clin Pharmacokinet. 1997. PMID: 9160173 Review.
-
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.Am J Cardiovasc Drugs. 2001;1(6):411-20. doi: 10.2165/00129784-200101060-00001. Am J Cardiovasc Drugs. 2001. PMID: 14728000 Review.
Cited by
-
Rescue of EndMT-associated endothelial dysfunction by modulating the YAP pathway.Nat Cardiovasc Res. 2023 May;2(5):420-422. doi: 10.1038/s44161-023-00268-0. Nat Cardiovasc Res. 2023. PMID: 39196047 No abstract available.
-
Thrombotic Microangiopathy in Pregnancy: Current Understanding and Management Strategies.Kidney Int Rep. 2024 May 22;9(8):2353-2371. doi: 10.1016/j.ekir.2024.05.016. eCollection 2024 Aug. Kidney Int Rep. 2024. PMID: 39156177 Free PMC article. Review.
-
Does high dose statin pretreatment affect global strains in patients undergoing valve replacement.Indian J Thorac Cardiovasc Surg. 2024 May;40(3):300-310. doi: 10.1007/s12055-023-01652-y. Epub 2023 Dec 22. Indian J Thorac Cardiovasc Surg. 2024. PMID: 38681712
-
Potential Benefits and Risks Associated with the Use of Statins.Pharmaceutics. 2024 Feb 1;16(2):214. doi: 10.3390/pharmaceutics16020214. Pharmaceutics. 2024. PMID: 38399268 Free PMC article. Review.
-
Mechanisms of 3-Hydroxyl 3-Methylglutaryl CoA Reductase in Alzheimer's Disease.Int J Mol Sci. 2023 Dec 22;25(1):170. doi: 10.3390/ijms25010170. Int J Mol Sci. 2023. PMID: 38203341 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical